220 related articles for article (PubMed ID: 11985384)
1. Interferon beta1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability.
Vermersch P; de Seze J; Stojkovic T; Hautecoeur P;
J Neurol; 2002 Feb; 249(2):184-7. PubMed ID: 11985384
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A; Murray TJ;
Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
[TBL] [Abstract][Full Text] [Related]
3. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
6. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Rudick RA; Goodkin DE; Jacobs LD; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Granger CV; Simon JH; Alam JJ; Simonian NA; Campion MK; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Whitham RH
Neurology; 1997 Aug; 49(2):358-63. PubMed ID: 9270562
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
Murray TJ
Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
[TBL] [Abstract][Full Text] [Related]
8. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis and depression: influence of interferon beta therapy.
Zephir H; De Seze J; Stojkovic T; Delisse B; Ferriby D; Cabaret M; Vermersch P
Mult Scler; 2003 Jun; 9(3):284-8. PubMed ID: 12814176
[TBL] [Abstract][Full Text] [Related]
10. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
Rudick RA; Pace A; Rani MR; Hyde R; Panzara M; Appachi S; Shrock J; Maurer SL; Calabresi PA; Confavreux C; Galetta SL; Lublin FD; Radue EW; Ransohoff RM
Neurology; 2009 Jun; 72(23):1989-93. PubMed ID: 19506220
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
Clanet M; Radue EW; Kappos L; Hartung HP; Hohlfeld R; Sandberg-Wollheim M; Kooijmans-Coutinho MF; Tsao EC; Sandrock AW;
Neurology; 2002 Nov; 59(10):1507-17. PubMed ID: 12451189
[TBL] [Abstract][Full Text] [Related]
12. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
13. [Open trial of the effectiveness of interferon beta 1a (Avonex) in multiple sclerosis. Clinical assessment using motor coordination tests].
Selmaj K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z
Neurol Neurochir Pol; 2003; 37(6):1163-83. PubMed ID: 15174231
[TBL] [Abstract][Full Text] [Related]
14. [Interferon beta-1a (Avonex TM): clinical and MRI impacts].
Vermersch P
Rev Neurol (Paris); 1999; 155 Suppl 2():S13-9. PubMed ID: 10367320
[TBL] [Abstract][Full Text] [Related]
15. Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data.
Mult Scler; 2001 Jun; 7(3):179-83. PubMed ID: 11475442
[TBL] [Abstract][Full Text] [Related]
16. Improving compliance with interferon-beta therapy in patients with multiple sclerosis.
Portaccio E; Amato MP
CNS Drugs; 2009; 23(6):453-62. PubMed ID: 19480465
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.
Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu G; Martinelli V; Milani N; Milanese C; Moiola L; Patti F; Pilato V; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
Mult Scler; 2005 Aug; 11(4):420-4. PubMed ID: 16042224
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
19. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
Rudick RA; Cookfair DL; Simonian NA; Ransohoff RM; Richert JR; Jacobs LD; Herndon RM; Salazar AM; Fischer JS; Granger CV; Goodkin DE; Simon JH; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munchsauer FE; O'Reilly K; Priore RL; Whitham RH
J Neuroimmunol; 1999 Jan; 93(1-2):8-14. PubMed ID: 10378864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
